{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:23:06Z","timestamp":1775024586132,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","award":["BioMarin Pharmaceutical"],"award-info":[{"award-number":["BioMarin Pharmaceutical"]}],"id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mucopolysaccharidosis (MPS) IVA is a rare disease with substantial, multisystemic morbidity. We assessed real-world safety and effectiveness of the enzyme replacement therapy (ERT) elosulfase alfa in patients with MPS IVA in the multinational, observational Morquio A Registry Study (MARS) who initiated ERT in adulthood (aged\u2009\u2265\u200918 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients were enrolled between September 2014 and February 2022; urinary keratan sulfate (uKS), 6-minute walk test (6MWT) distance, forced expiratory volume in 1\u00a0s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ), forced vital capacity (FVC), EuroQoL-5D-5L (EQ-5D-5L) score, and safety were assessed during routine care.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      As of February 13, 2022, 90 patients who initiated ERT had enrolled (median exposure: 5.6 years; median age at first ERT: 27.8 years). Reductions from baseline in uKS levels were sustained over mean follow-up of 5.4 years (mean percent change: -52.9%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). In patients with available data, mean change in 6MWT distance was +\u200915.8\u00a0m (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.3627) over a mean follow-up of 5.8 years. FEV\n                      <jats:sub>1<\/jats:sub>\n                      and FVC remained stable over mean follow-up of 5.3 years (mean change: 0.0\u00a0L for both). The mean change from baseline in EQ-5D-5L index score was +\u20090.1 after 1 year of treatment. Thirty-four patients (39.5%) had\u2009\u2265\u20091 adverse event (AE), 23 patients (26.7%) had\u2009\u2265\u20091 serious AE, and 10 (11.6%) had\u2009\u2265\u20091 drug-related AE (infusion-related reactions [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093; 3.5%], pyrexia [\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092; 2.3%]). Eight deaths occurred; none were deemed treatment related.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Real-world data collected from MARS suggest that patients with MPS IVA who initiated ERT in adulthood remained stable over 7 years of follow-up. No new safety signals were identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04064-w","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:20:40Z","timestamp":1761816040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term outcomes of elosulfase alfa enzyme replacement therapy in adults with MPS IVA: a sub-analysis of the Morquio A Registry Study (MARS)"],"prefix":"10.1186","volume":"20","author":[{"given":"Karolina M.","family":"Stepien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara K.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Bober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe M.","family":"Campeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Ellaway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaustuv","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Guffon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hinds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Lail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuan-Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Magner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Reisewitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"2","key":"4064_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","volume":"30","author":"AM Monta\u00f1o","year":"2007","unstructured":"Monta\u00f1o AM, Tomatsu S, Gottesman G, Smith M, Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30(2):165\u201374.","journal-title":"J Inherit Metab Dis"},{"issue":"1\u20132","key":"4064_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ymgme.2013.04.002","volume":"110","author":"C Hendriksz","year":"2013","unstructured":"Hendriksz C, Harmatz P, Beck M, Jones S, Wood T, Lachman R, et al. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol Genet Metab. 2013;110(1\u20132):54\u201364.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4064_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","volume":"109","author":"P Harmatz","year":"2013","unstructured":"Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin SP, Parini R, et al. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109(1):54\u201361.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"4064_CR4","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3390\/ijms21041517","volume":"21","author":"K Sawamoto","year":"2020","unstructured":"Sawamoto K, \u00c1lvarez Gonz\u00e1lez JV, Piechnik M, Otero FJ, Couce ML, Suzuki Y, et al. Mucopolysaccharidosis IVA: diagnosis, treatment, and management. Int J Mol Sci. 2020;21(4):1517.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4064_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ymgme.2014.10.015","volume":"114","author":"PR Harmatz","year":"2015","unstructured":"Harmatz PR, Mengel KE, Giugliani R, Valayannopoulos V, Lin S-P, Parini R, et al. Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome. Mol Genet Metab. 2015;114(2):186\u201394.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4064_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/ajmg.a.36833","volume":"167","author":"CJ Hendriksz","year":"2015","unstructured":"Hendriksz CJ, Berger KI, Giugliani R, Harmatz P, Kampmann C, Mackenzie WG, et al. International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet. 2015;167(1):11\u201325.","journal-title":"Am J Med Genet"},{"key":"4064_CR7","unstructured":"US Food and Drug Administration, Vimizim (elosulfase alfa). US prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125460s017lbl.pdf. Accessed May 15, 2024."},{"key":"4064_CR8","unstructured":"European Medicines Agency. Vimizim, Summary of Product Characteristics. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vimizim-epar-product-information_en.pdf. Accessed May 15, 2024."},{"issue":"1","key":"4064_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13023-019-1074-9","volume":"14","author":"MU Akyol","year":"2019","unstructured":"Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, et al. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14(1):137.","journal-title":"Orphanet J Rare Dis"},{"key":"4064_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","volume":"37","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Burton B, Fleming TR, Harmatz P, Hughes D, Jones SA, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014;37:979\u201390.","journal-title":"J Inherit Metab Dis"},{"key":"4064_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10545-016-9973-6","volume":"39","author":"CJ Hendriksz","year":"2016","unstructured":"Hendriksz CJ, Berger KI, Parini R, AlSayed MD, Raiman J, Giugliani R, et al. Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome. J Inherit Metab Dis. 2016;39:839\u201347.","journal-title":"J Inherit Metab Dis"},{"issue":"1\u20132","key":"4064_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ymgme.2016.05.018","volume":"119","author":"CJ Hendriksz","year":"2016","unstructured":"Hendriksz CJ, Parini R, AlSayed MD, Raiman J, Giugliani R, Villarreal MLS, et al. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome. Mol Genet Metab. 2016;119(1\u20132):131\u201343.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4064_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ymgme.2014.08.012","volume":"114","author":"CJ Hendriksz","year":"2015","unstructured":"Hendriksz CJ, Giugliani R, Harmatz P, Mengel E, Guffon N, Valayannopoulos V, et al. Multi-domain impact of elosulfase alfa in Morquio A syndrome in the pivotal phase III trial. Mol Genet Metab. 2015;114(2):178\u201385.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"4064_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-017-0634-0","volume":"12","author":"D Hughes","year":"2017","unstructured":"Hughes D, Giugliani R, Guffon N, Jones SA, Mengel KE, Parini R, et al. Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa. Orphanet J Rare Dis. 2017;12(1):1\u20138.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4064_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ymgme.2017.11.015","volume":"123","author":"CJ Hendriksz","year":"2018","unstructured":"Hendriksz CJ, Parini R, AlSayed MD, Raiman J, Giugliani R, Mitchell JJ, et al. Impact of long-term elosulfase alfa on activities of daily living in patients with Morquio A syndrome in an open-label, multi-center, phase 3 extension study. Mol Genet Metab. 2018;123(2):127\u201334.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4064_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/diagnostics10020108","volume":"10","author":"S Barak","year":"2020","unstructured":"Barak S, Anikster Y, Sarouk I, Stern E, Eisenstein E, Yissar T, et al. Long-term outcomes of early enzyme replacement therapy for mucopolysaccharidosis IV: clinical case studies of two siblings. Diagnostics. 2020;10(2):108.","journal-title":"Diagnostics"},{"issue":"1","key":"4064_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-020-01618-y","volume":"15","author":"C Ficicioglu","year":"2020","unstructured":"Ficicioglu C, Matalon DR, Luongo N, Menello C, Kornafel T, Degnan AJ. Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study. Orphanet J Rare Dis. 2020;15(1):1\u201310.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4064_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-01761-0","volume":"16","author":"S K\u0131lavuz","year":"2021","unstructured":"K\u0131lavuz S, Basaran S, Kor D, Bulut FD, Erdem S, Ball\u0131 HT, et al. Morquio A syndrome and effect of enzyme replacement therapy in different age groups of Turkish patients: a case series. Orphanet J Rare Dis. 2021;16(1):1\u201310.","journal-title":"Orphanet J Rare Dis"},{"issue":"1\u20132","key":"4064_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2022.08.007","volume":"137","author":"JJ Mitchell","year":"2022","unstructured":"Mitchell JJ, Burton BK, Bober MB, Campeau PM, Cohen S, Dosenovic S, et al. Findings from the Morquio A registry study (MARS) after 6 years: long-term outcomes of MPS IVA patients treated with elosulfase Alfa. Mol Genet Metab. 2022;137(1\u20132):164\u201372.","journal-title":"Mol Genet Metab"},{"key":"4064_CR20","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336.","journal-title":"Qual Life Res"},{"key":"4064_CR21","unstructured":"EuroQol, Group, EQ-5D-5L User Guide. 2019. https:\/\/euroqol.org\/information-and-support\/documentation\/user-guides\/. Accessed May 15, 2024."},{"issue":"1\u20132","key":"4064_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ymgme.2013.06.008","volume":"110","author":"VC D\u0169ng","year":"2013","unstructured":"D\u0169ng VC, Tomatsu S, Monta\u00f1o AM, Gottesman G, Bober MB, Mackenzie W, et al. Mucopolysaccharidosis IVA: correlation between genotype, phenotype and Keratan sulfate levels. Mol Genet Metab. 2013;110(1\u20132):129\u201338.","journal-title":"Mol Genet Metab"},{"key":"4064_CR23","first-page":"103428","volume":"3","author":"B Burton","year":"2025","unstructured":"Burton B, Stepien K, Campeau P, Sutton J, Hunt A, Reisewitz P, et al. Real-world treatment with elosulfase alfa in MPS IVA is associated with improved endurance over time. GIM Open. 2025;3:103428.","journal-title":"GIM Open"},{"issue":"10","key":"4064_CR24","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/ajmg.a.32281","volume":"146","author":"AM Monta\u00f1o","year":"2008","unstructured":"Monta\u00f1o AM, Tomatsu S, Brusius A, Smith M, Orii T. Growth charts for patients affected with Morquio A disease. Am J Med Genet. 2008;146(10):1286\u201395.","journal-title":"Am J Med Genet"},{"key":"4064_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-020-01545-y","volume":"15","author":"L Moisan","year":"2020","unstructured":"Moisan L, Iannuzzi D, Maranda B, Campeau PM, Mitchell JJ. Clinical characteristics of patients from Quebec, Canada, with Morquio A syndrome: a longitudinal observational study. Orphanet J Rare Dis. 2020;15(1):270.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4064_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-9-32","volume":"9","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Lavery C, Coker M, Ucar SK, Jain M, Bell L, et al. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis. 2014;9(1):1\u20138.","journal-title":"Orphanet J Rare Dis"},{"key":"4064_CR27","doi-asserted-by":"crossref","unstructured":"Lavery C, Hendriksz C. Mortality in patients with Morquio syndrome A. JIMD Rep. 2015;(15):59\u201366.","DOI":"10.1007\/8904_2014_298"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04064-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04064-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04064-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:20:42Z","timestamp":1761816042000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04064-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4064"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04064-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The MARS study protocol was reviewed and approved by all applicable institutional review boards and ethics committees for participating study sites. All participants gave written informed consent, or, in the case of individuals aged < 18 years, written consent was obtained from a legally authorized representative. All publications related to the MARS registry have been overseen by a dedicated Scientific Publication Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approvals and consent for participation"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KMS is a Principal Investigator in MARS for BioMarin Pharmaceutical Inc. BKB has received consulting payments from Aeglea, Agios, Altrna, Aro, BioMarin Pharmaceutical Inc., JCR Pharma, Jnana, Maze, Moderna, Passage Bio, PTC Therapeutics, Takeda, and Travere; has participated as a clinical trial investigator for BioMarin Pharmaceutical Inc., Denali, JCR Pharma, Sangamo, and Ultragenyx; and has received speaker fees\/payments from BioMarin Pharmaceutical Inc., Chiesi, Horizon, Takeda, and Ultragenyx. MBB is an employee and owner of Tyra Biosciences; and has received consulting payments from and participated as a clinical trial investigator for BioMarin Pharmaceutical Inc. PMC has provided consultation\/advisory services for BioMarin Pharmaceutical Inc., Ipsen, and Sanofi. CE has received honorarium for participation in a MARS Medical Advisory Board from BioMarin Pharmaceutical Inc. KB has nothing to report. NG has received consulting payments and travel support from and participated as a clinical trial investigator in MARS for BioMarin Pharmaceutical Inc.; is a Principal Investigator in clinical trials for Chiesi, JCR Pharma, Sanofi, Takeda, and Ultragenyx; and has received consulting\/speaker fees from Chiesi, JCR Pharma, Sanofi, and Ultragenyx. DH, AH, and PR are employees of and may hold stock ownership and shareholdings in BioMarin Pharmaceutical Inc. AL has nothing to report. S-PL has provided advisory board services to BioMarin Pharmaceutical Inc. MM has received lecture honoraria and consultancy fees from BioMarin Pharmaceutical Inc., Chiesi, and Takeda. EM has participated as a clinical trial investigator for BioMarin Pharmaceutical Inc. JJM has received consulting payments from BioMarin Pharmaceutical Inc., Denali, Sanofi-Genzyme, Takeda, and Ultragenyx; has received research grants from BioMarin Pharmaceutical Inc., Sanofi-Genzyme, and Takeda; and has participated as a clinical trial investigator in MARS for BioMarin Pharmaceutical Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"548"}}